Skip to main content
PLOS One logoLink to PLOS One
. 2026 Mar 19;21(3):e0344692. doi: 10.1371/journal.pone.0344692

Hypochloremia, non-medication related associated factors, and impact on clinical outcomes in patients with acute heart failure: Insights from resource limited setups

Belay Mengistu Gebrie 1, Molla Asnake Kebede 2,*, Kedir Negesso Tukeni 2, Mohammed Mecha Abafogi 2, Turi Abateka Abadiga 3, Bethelhem Yaynemsa Sequr 1, Biniyam Beyene Tabor 4, Selemon Gebrezgabiher Asgedom 5
Editor: Innocent Ijezie Chukwuonye6
PMCID: PMC13001925  PMID: 41855170

Abstract

Background

Electrolyte disturbances such as hypochloremia are common in patients with acute heart failure (AHF) and may worsen clinical outcomes. However, data from low-resource settings remain limited. Therefore, the aim of this study is to determine the prevalence of hypochloremia among AHF patients, assess its association with length of hospital stay and in-hospital mortality, and identify factors independently associated with its occurrence.

Objective

To determine the prevalence of hypochloremia among patients admitted with acute heart failure, to assess its non-medication association with length of hospital stay and in-hospital mortality, and to identify factors independently associated with hypochloremia in a resource-limited setting.

Methods

A retrospective observational cohort study of hospitalized patients with acute heart failure, with serum chloride measured at admission was conducted among 260 patients aged ≥16. Data were analysed using SPSS version 26.0. The association between hypochloremia and clinical outcomes, including in-hospital mortality and length of hospital stay, was assessed using the Chi-square test and the Mann–Whitney U test, respectively. Multivariable logistic regression analysis was performed to identify independent predictors of hypochloremia. A p-value of <0.05 was considered statistically significant.

Results

The prevalence of hypochloremia was 33.1% (95% CI: 27.4%–39.2%), and hypochloremic patients had significantly longer hospital stays (median: 12 days vs. 8.5 days; p = 0.001) and higher in-hospital mortality (χ² = 8.58; p = 0.003). Multivariate analysis showed that NYHA class IV heart failure [AOR = 6.96; 95% CI: 1.49–32.4; p = 0.014], history of COPD [AOR = 4.94; 95% CI: 1.36–17.9; p = 0.001], hyponatremia [AOR = 2.20; 95% CI: 1.8–9.5; p = 0.001], and hypokalemia [AOR = 4.08; 95% CI: 1.53–10.6; p = 0.004] were significantly associated with hypochloremia.

Conclusion

In this study hypochloremia at admission was common and associated with higher in-hospital mortality and longer hospital stays. It was more frequently observed in patients with severe heart failure, COPD, hypokalemia and hyponatremia.

Background

Acute heart failure (AHF) is a complex clinical syndrome characterized by rapid onset or worsening of heart failure symptoms, often leading to emergency hospitalization. It is a major public health concern with high morbidity, mortality, and resource utilization globally, particularly in low- and middle-income countries [1,2]. In-hospital mortality from AHF remains significant despite therapeutic advancements, and identifying early prognostic markers is crucial for improving outcomes [3].

Electrolyte imbalances are frequent among patients with AHF, influenced by neurohormonal activation, renal dysfunction, and pharmacologic interventions such as loop diuretics. While disturbances in sodium and potassium are commonly evaluated, the prognostic value of chloride has received comparatively little attention. Emerging evidence suggests that hypochloremia, defined as serum chloride levels below 98 mmol/L, may serve as an independent predictor of poor outcomes in both chronic and acute heart failure settings [3,4]. Several mechanisms may explain this association. Hypochloremia is known to activate the renin–angiotensin–aldosterone system (RAAS), reduce responsiveness to diuretics, and reflect severe neurohormonal derangement factors contributing to worse prognosis [5,6]. Studies have linked hypochloremia with increased in-hospital mortality, longer length of hospital stay, higher rates of diuretic resistance, and readmissions [7,8].

Despite these findings, there is a paucity of data regarding the prevalence, predictors, and clinical impact of hypochloremia among patients with AHF in sub-Saharan Africa. This gap is particularly relevant in Ethiopia, where diagnostic and treatment capacities are variable, and disease patterns may differ from those in high-income settings. Therefore, this study aimed to assess the association between hypochloremia and in-hospital mortality and length of hospital stay in AHF patients, and to identify independent predictors of hypochloremia in this population.

Method and materials

Study setting and period

The study was conducted at Jimma Medical Center (JMC), a major teaching and referral hospital located in Jimma Town, Oromia Region, Southwest Ethiopia. JMC serves an estimated population of approximately 2.77 million people from the surrounding zones. Data were collected from March 27 to May 30, 2025, and included patient charts for individuals admitted between December 1, 2022, and December 1, 2024.

Study design and population

A retrospective observational cohort study of hospitalized patients with acute heart failure, with serum chloride measured at admission. It was conducted among patients aged ≥16 years to JMC during the study period.

Eligibility criteria.

All ≥ 16 years old, patients with acute heart failure who admitted to Jimma university medical center and determined serum chlorine level on admission. Patients without serum chloride levels at admission were excluded.

Sample size determination and sampling technique

A single population proportion formula was used to calculate the sample size by using 36.7% of prevalence of hypochloremia among acute heart failure patients in Ethiopia, 95% confidence interval (CI), and margin of error of 5%.

n= (Z α/2)2*p(1p)d2

Where

n = sample size

Z = cut off value of the normal distribution at 95% CI = 1.96

P= proportion of hypochloremia among acute heart failure patients= 0.367

d= marginal error= 0.05

n= (1.96)2*0.367(10.367)(0.05)2

n = 357

The source population was less than 10,000(N = 700 from internal hospital statistics in the study period). Then sample size was corrected by using a correction formula.

 Corrected sample size =n 1+n/N=260\]

Systematic random sampling technique was used. k is calculated as N/n and every 2 interval, randomly selected patients who fulfill inclusion criteria were included until the calculated sample size is obtained (Fig 1)

Fig 1. Flow diagram of study population selection.

Fig 1

Flowchart illustrating the screening, eligibility assessment, exclusions, and final inclusion of patients admitted with acute heart failure at Jimma Medical Center between December 2022 and December 2024. A total of 260 patients were evaluated for eligibility. The diagram details the number of patients excluded and the final number included in the analysis.

For our secondary objective, factors associated with hypochloremia were estimated using the double population proportion formula in Epi Info Version 7 (STATCALC), considering variables such as hyponatremia, NYHA class IV, and loop diuretic use from previous studies [9,10,11]. The largest calculated sample (n = 126) was smaller than the primary objective sample; therefore, the final sample size remained 260. A systematic random sampling technique was applied to select study participants.

Study variables

Data was collected on a range of socio-demographic, clinical, laboratory, treatment, and outcome variables. Socio-demographic variables included age, sex, and residence. Clinical variables comprised type of heart failure (acute decompensated or new onset), NYHA functional class, underlying etiology, left ventricular ejection fraction (LVEF), vital signs, pulmonary congestion, peripheral edema, and comorbidities such as hypertension, diabetes mellitus, chronic obstructive pulmonary disease (COPD), atrial fibrillation, and anemia.

Laboratory variables included serum chloride, sodium, potassium, hemoglobin, creatinine, and blood urea nitrogen (BUN). The primary variable, serum chloride, was measured at admission as a continuous variable, with hypochloremia defined as serum chloride <98 mmol/L. Treatment variables covered the use of loop diuretics, renin-angiotensin-aldosterone system (RAAS) inhibitors, beta-blockers, SGLT2 inhibitors, statins, and aspirin.

Primary exposure.

Hypochloremia at admission

Primary outcomes.

In‑hospital mortality

length of hospital stays

Operational definition.

Acute Heart Failure (AHF): Rapid onset or worsening of heart failure symptoms requiring hospitalization, including both new onset and acute decompensated heart failure cases [12].

Hypochloremia: Serum chloride level less than 98 mmol/L measured at admission [13].

NYHA Functional Class: Classification of heart failure severity based on symptoms during physical activity, categorized as Class I–IV [12].

Heart Failure Types: [12]

HFrEF: LVEF < 40%

HFmrEF: LVEF 41–49%

HFpEF: LVEF ≥ 50%.

Length of Hospital Stay: Number of days from admission to discharge or in-hospital death [14].

In-hospital Mortality: Death occurring during hospital admission [15].

Pulmonary Congestion: Clinical or radiological evidence of fluid accumulation in lungs [12].

Peripheral Edema: Swelling in lower extremities detected on physical exam [16].

Hyponatremia: Serum sodium level less than 135 mmol/L [17].

Hypokalemia: Serum potassium level less than 3.5 mmol/L [18].

Data collection procedure

Data were collected retrospectively using a structured English checklist that captured patient demographics, clinical characteristics, laboratory results, comorbidities, treatments, and outcomes. Two trained internal medicine residents extracted data from medical records using the Kobo Toolbox application under close supervision of the principal investigator to ensure data accuracy and completeness.

Data quality control

Data quality was ensured throughout the study. The checklist was pretested on 5% of the sample at a separate hospital to ensure clarity and applicability. Data collectors received comprehensive training before data extraction. Completed checklists were reviewed daily for completeness, consistency, and accuracy, and discrepancies were corrected promptly. Prior to analysis, data were cleaned and cross-checked for errors. The principal investigator oversaw data management and secure storage throughout the study period. All included patients (n = 260) had complete data for serum chloride and all covariates included in the analysis. No missing data was observed for the variables analyzed, as a result no imputation methods were applied.

Data analysis

Data were exported to SPSS version 26.0 for analysis. Descriptive statistics were used to summarize the data: means and standard deviations for continuous variables, and frequencies with percentages for categorical variables. Differences in in-hospital mortality between hypochloremic and non-hypochloremic patients were analyzed using the Chi-square test. The Shapiro-Wilk test assessed data normality, and since the length of hospital stay was non-normally distributed, comparisons were made using the Mann-Whitney U test. Bivariate logistic regression was used to explore associations between independent variables and hypochloremia. Variables with a p-value < 0.25 were included in the multivariable binary logistic regression model to determine independent predictors. Results were reported as adjusted odds ratios (AORs) with 95% confidence intervals (CIs), and statistical significance was set at p < 0.05. Model fitness was evaluated using the Hosmer-Lemeshow goodness-of-fit test.

Ethical statement

Ethical clearance was obtained from the Institutional Review Board of Jimma University Institute of Health. Ref. number: JUIH/ IRB/ 222/25. This study was conducted in accordance with the principles of the Declaration of Helsinki. The study used retrospective data collected from medical records; therefore, the Institutional Review Board of Jimma University waived the requirement for informed consent from individual patients. No personal identifiers were recorded, and all data were fully anonymized prior to analysis. Collected data were securely stored in the Jimma University research data repository and can be accessed upon request via the office email at ero@ju.edu.et and strict confidentiality was maintained throughout the study. The anonymized data set is attached to this manuscript.

Results

Socio-demographic characteristics

A of total 260 acute heart failure patients who had a determination of chloride level on admission were included in this study. The age of Participants ranged from 16 to 90 years with mean age 51.6 ± 18.4SD. The majority of the study participants 156 (60%) were male and 104(40%) were female. Out of total study subjects 184(70.8%) were rural residents and 76(29.2%) were urban residents.

Clinical characteristics

Out of the total 260 study participants, 187(71.9%) had acute decompensated heart failure whereas 73(28.1%) had new onset (de novo) heart failure and almost all study participants 259(99.6%) had stage C heart failure. Most common current underlying HF diagnosis was ischemic heart disease 89(34.2%) followed by CRVHD 86(33.4%) and the least common underlying HF diagnosis was RCMP 4(1.5%). 118(45.8%) of study participants had a history of hospitalization due to heart failure. Majority of the study participants, 175(67.3%) had NYHA class III whereas 5 (1.9%) had NYHA class I. The mean LVEF of the study participant was 45.5 ± 15SD with minimum 18 and maximum 70. Overall, 119(45.8%) had heart failure with reduced ejection fraction (HFrEF), 116(44.6%) had heart failure with preserved ejection fraction (HFpEF), and 25(9.6%) had heart failure with mildly reduced ejection fraction. Nearly half of study subjects, 134 (51.5%, had pulmonary congestion.

The mean SBP value and mean DBP value of study subjects were 111.3 ± 17.1 mmHg SD and 69.7 ± 10.2 mmHg SD respectively. Of the total study subjects, 61(23.5%) was greater than 120 mmHg systolic blood pressure, 7(2.7%) had less than 90 mmHg systolic blood pressure, 34(13.1%) had greater than 80 mmHg diastolic blood pressure, 13(5.0%) had less than 60 mmHg diastolic blood pressure, 93(35.8%) had pulse rate greater than 100 beat/minute. Majority of the participants, 244(93.8%) had peripheral edema (Table 1)

Table 1. Clinical characteristics among adult patients with acute heart failure admitted to Jimma Medical Center, December 2022–December 2024 (n = 260).

Variables Frequency (%)
Current underlying HF diagnosis
ACS 26(10%)
Corpulmonale 5(1.9%)
CRVHD 86(33.1%)
DCMP 45(17.3%)
HHD 5(1.9%)
IHD 89(34.2%)
RCMP 4(1.5%)
Category of Heart failure
Acute decompensated heart failure 187(71.9%)
De novo (new onset) 73(28.1%)
NYHA functional classification
Class I 5(1.9%)
Class II 43(16.5%)
Class III 175(67.3%)
Class IV 37(14.2%)
Heart failure type
HFmrEF 25(9.6%)
HFpEF 116(44.6%)
HFrEF 119(45.8%)
Systolic blood pressure category
90 to 120 mmHg 192(73.8%)
Less than 90 mmHg 7(2.7%)
Greater than 120 mmHg 61(23.5%)
Diastolic blood pressure category
60 to 80 mmHg 213(81.9%)
Less than 60 mmHg 13(5.0%)
Greater than 80 mmhg 34(13.1%)
Pulse rate category
Less than 100 beat/min 167(64.2%)
Greater than 100 beats/min 93(35.8%)

NB: HF = heart failure, ACS = acute coronary syndrome, CRVHD = chronic rheumatic valvular heart disease, DCMP = dilated cardiomyopathy, HHD = hypertensive heart disease, IHD = ischemic heart disease, RCMP = restrictive cardiomyopathy, NYHA = New York Heart Association, HFmrEF = heart failure with mildly reduced ejection fraction, HFpEF = heart failure with preserved ejection fraction, and HFrEF = heart failure with reduced ejection fraction.

Regarding the comorbidities, out of total participants, 96(36.9%) had hypertension, 29(11.2%) had diabetic mellitus, 21(8.1%) had chronic kidney disease, 16(6.2%) had chronic obstructive pulmonary disease(COPD), 78(30.0%) had atrial fibrillation, 89(34.2%) had anemia, 10(3.8%) had thyrotoxicosis, and only one study participant had retroviral infection (Fig 2)

Fig 2. Prevalence of comorbidities among adult patients admitted with acute heart failure.

Fig 2

Bar chart showing the distribution and prevalence of comorbid conditions among 260 adult patients admitted with acute heart failure at Jimma Medical Center between December 2022 and December 2024. COPD = Chronic Obstructive Pulmonary Disease.

Laboratory data

The mean value serum sodium level was 135.9 mmol/L with standard deviation of 5.9 mmol/L and 90(34.6%) of the participants had low serum sodium level. The mean level of serum potassium of study subjects was 4 mmol/L ± 0.7 mmol/L SD and abo

ut 43(16.5%) had hypokalemia. The minimum and maximum values of hemoglobin level in this group of patients were 5.6g/dl and 18 g/dl, respectively with mean of 12.5g/dl and standard deviation of 2.2g/dl. The mean levels of serum creatinine and blood urea nitrogen were 1.2 mg/dl ± 1.1 mg/dl SD and 38.4 mg/dl ± 26 mg/dl SD respectively.

Treatment related characteristics

Out of the total, 252(96.9%) of study participants were on diuretics treatment. Out of these 252 participants, all of them were on loop diuretics and only 2 of study participants on thiazide diuretics. The mean daily dose of loop diuretics that study participants received was 92.3 mg ± 39.7 mg SD, with a minimum of 20 mg/day and a maximum of 240 mg/day. 167(64.2%) of study subject were treated with renin-angiotensin-aldosterone system inhibitors, 227(87.3%) were treated with beta blockers, 33(12.7%) were on sodium-glucose cotransporter-2 (SGLT2) inhibitors, 127(48.8%) were on statin (atorvastatin), 128(49.2%) were on aspirin.

The mean length of hospital stay was 11.2 ± 6.9days SD with minimum, 2 days and maximum, 48 days. Out of total participants, 239 (91.9%) were discharged with improvement and 21(8.1%) in hospital deaths were observed.

Prevalence of hypochloremia

The minimum and maximum values of serum chloride level were 70 mmol/L and 136 mmol/L, respectively with mean of 99.3 mmol/L and standard deviation of 8.4 mmol/L. Out of the total study participants, hypochloremia was observed in 86(33.1%) of study participants. Out of those who had hypochloremia at admission, hypochloremia of 45(52.3%) participants were corrected and hypochloremia of 41(47.7%) participants were not corrected after admission.

Outcomes of hypochloremia in patients with AHF

he results showed that in-hospital death was significantly higher among patients with hypochloremia (15.1%) compared to those with normal serum chloride levels (4.5%) (χ²(1) = 8.58, p = 0.003). The test confirmed that this difference was statistically significant. The Kolmogorov = Smirnov and Shapiro-Wilk tests were used to assess the normality of the length of hospital stay, and the data were found to be non-normally distributed even after log transformation. Therefore, a Mann-Whitney U test was employed. The analysis revealed that patients with hypochloremia had a significantly longer hospital stay (median: 12 days) compared to those with normal chloride levels (median: 8.5 days) (p = 0.001).

Factors associated with hypochloremia among AHF patients

The outcome of multivariate logistic regression stated that NYHA classification HF, history of COPD, hyponatremia, and hypokalemia were factors significantly associated with hypochloremia at p < 0.05. Patients with NYHA class IV heart failure were seven times more likely to develop hypochloremia when compared to NYHA class I and II heart failure patients [AOR = 6.96, 95%CI: 1.49–32.4, p 0.014]. The odds of developing hypochloremia among heart failure patients having history of chronic obstructive pulmonary disease were five times higher as compared to those who didn’t have history of COPD [AOR4.94, 95%CI: 1.36–17.9, p 0.001]. Compared to HF patients with normal sodium, those with hyponatremia were 2.2 times more likely to develop hypochloremia [AOR 2.2, 95%CI: 1.8–9.5, p 0.001]. Heart failure patients with hypokalemia have four times odds of developing hypochloremia as compared to those normal potassium [AOR 4.08, 95%CI: 1.53–10.6, p 0.004] (Table 2).

Table 2. Factors associated to hypochloremia among adult patients with acute heart failure admitted to Jimma Medical Center, December 2022–December 2024 (n = 260).

Variables Categories Hypochloremia COR(95%CI) P value AOR(95%CI) p-value
Yes No
NYHA classification Class I & II 5 43 1 1
Class III 61 114 4.6(1.73-12.3) 0.453 3.05(0.85-10.9) 0.087
Class IV 20 17 10.1(3.72-31.3) 0.089 6.96(1.49-32.4) 0.014*
Hospitalization history due to HF No 39 103 1 1
Yes 47 71 1.74(1.03-2.9) 0.341 1.75(0.82-3.73) 0.15
Type of HF HFpEF 30 86 1 1
HFrEF 56 88 1.82(1.07-3.11) 0.103 1.29(0.58-2.87) 0.53
Pulmonary congestion No 30 96 1 1
Yes 56 78 2.29(1.35-3.92) 0.212 1.83(0.86-3.9) 0.12
Systolic blood pressure ≤ 120 mmHg 71 128 1 1
> 120 mmHg 15 46 0.59(0.31-1.13) 0.153 0.59(0.22-1.64) 0.32
Diastolic blood pressure ≤ 80 mmHg 80 146 1 1
> 80 mmHg 6 28 0.39(0.16-0.98) 0.095 0.36(0.09-1.44) 0.15
Pulse rate ≤ 100/min 48 119 1 1
> 100/min 38 55 1.71(1.01-2.92) 0.157 1.62(0.73-3.60) 0.23
Peripheral edema No 3 13 1 1
Yes 83 161 2.23(0.62-8.06) 0.182 0.64(0.1-4.38) 0.65
COPD No 77 167 1 1
Yes 9 7 2.79(1.01-7.76) 0.031 4.94(1.36-17.9) 0.001*
Anemia No 44 127 1 1
Yes 42 47 2.58(1.5-4.42) 0.189 1.18(0.55-2.53) 0.67
Hyponatremia No 20 150 1 1
Yes 66 24 20.6(10.6-39.9) 0.112 2.2(1.8-9.5) 0.001*
Hypokalemia No 56 161 1 1
Yes 30 13 6.63(3.2-13.6) 0.051 4.08(1.57-10.6) 0.004*

* = indicate significance at <0.05, COPD: chronic obstructive pulmonary disease, NHYA: New York heart association, HF: Heart failure, HFpEF: Heart failure with preserved ejection fraction, HFrEF: Heart failure with reduced ejection fraction.

Discussion

Despite the significant clinical impact of hypochloremia among heart failure (HF) patients, there remains limited data on its prevalence and associated factors among acute heart failure (AHF) patients in Africa. This study aimed to fill that gap and revealed alarming findings: one-third of AHF patients had hypochloremia. Furthermore, hypochloremia was associated with a longer length of hospital stay and higher in-hospital mortality. Age, NYHA functional class IV, history of chronic obstructive pulmonary disease (COPD), hyponatremia, and hypokalaemia were found to be significantly associated with hypochloremia in this population. The global burden of heart failure and related electrolyte disturbances highlights the clinical importance of these findings [19,20].

The prevalence of hypochloremia among acute heart failure (AHF) patients in the current study was 33.1% (95% CI: 27.4%–39.2%), which is considerably higher than reported in the United Kingdom (10.7%), Japan (12.5%) [21], the United States (13.0%) [22], China (26.1%), and North America (18.0%). This disparity may be attributed to multiple factors. The extensive use of loop diuretics in our study population could be a major contributor, as these agents are known to increase urinary chloride excretion and significantly raise the risk of hypochloremia in heart failure patients [9,11]. Dietary differences may also play a role; for instance, in Japan, high chloride intake from seafood such as fish, kelp, and seaweed may protect against hypochloremia [23]. In contrast, limited dietary diversity and food insecurity in our setting may result in lower chloride intake. Other contributing factors may include delayed presentation of patients, more advanced disease severity on admission, differences in healthcare access, and variations in laboratory reference ranges and diagnostic criteria, all of which can influence the observed prevalence. Our finding aligns more closely with studies conducted in Ethiopia (36.7%), as well as others from the USA (31.5%) [10] and (36.0%) [24]. These similarities may reflect regional practices in diuretic use, nutritional status, and underlying patient characteristics [13,25].

Importantly, the study found that the median length of hospital stay was longer among patients with hypochloremia (12 days) compared to those with normal chloride levels (8.5 days), a difference that was statistically significant (p = 0.001). This observation aligns with previous research showing that hypochloremia is independently associated with prolonged hospitalization in patients with acute and chronic heart failure [26]. The pathophysiological mechanisms underlying this association may include more severe neurohormonal activation, impaired renal function, and poor diuretic responsiveness among hypochloremic patients, all of which can complicate clinical management and delay recovery [27,9]. Hypochloremia may also serve as a surrogate marker for disease severity and ongoing volume overload, prompting clinicians to pursue more aggressive or prolonged treatment strategies. Moreover, the need for closer monitoring and frequent adjustments in diuretic therapy in patients with electrolyte imbalances may contribute to extended hospitalization. These findings highlight the association between hypochloremia and clinical outcomes in patients admitted with AHF. We suggest that further studies to explore whether early identification and management of electrolyte disturbances such as hypochloremia could independently influence patient outcomes and healthcare utilization. [28,29].

Moreover, in-hospital mortality was significantly higher among hypochloremic AHF patients (15.1%) compared to those with normal chloride levels (4.5%), with this difference reaching statistical significance (p = 0.003). This finding is consistent with studies from China, which reported a significantly increased 30-day mortality risk in hypochloremic AHF patients relative to those with normal chloride levels [28], as well as similar results observed in North America [30]. A comparable study conducted in Ethiopia also demonstrated higher in-hospital mortality among hypochloremic AHF patients [31]. The association between hypochloremia and poor outcomes may be explained by its effects on fluid balance and neurohormonal activation, which can exacerbate heart failure severity and contribute to diuretic resistance [12,9]. These mechanisms underscore the relevance of monitoring hypochloremia in patients with AHF. Collectively, our findings highlight the association between hypochloremia and adverse outcomes in AHF, suggesting areas for further research to evaluate potential clinical implications.

Furthermore, this study identified several factors significantly associated with hypochloremia: older age, NYHA class IV, history of COPD, hyponatremia, and hypokalemia. These findings are consistent with multiple studies. For example, older age has been consistently associated with an increased risk of hypochloremia in HF patients, possibly due to age-related renal function decline and altered electrolyte handling [32]. A study conducted in China involving 2,008 HF patients found that hypochloremia was significantly associated with more severe functional status (higher NYHA class), reflecting the greater neurohormonal activation and diuretic use in advanced HF that can lead to electrolyte imbalances [22,26]. Comorbidities such as COPD and respiratory failure are more prevalent in hypochloremic patients, potentially might be because of chronic hypoxia and increased use of diuretics or corticosteroids that affect electrolyte balance [33,29]. Moreover, electrolyte disturbances, particularly hyponatremia and hypokalemia, commonly co-occur with hypochloremia in HF patients might indicate shared underlying mechanisms such as diuretic therapy and neurohormonal dysregulation [34,26].

While our study focused on hypochloremia at admission, we were unable to differentiate patients whose hypochloremia persisted during hospitalization from those whose levels normalized, which may have implications for outcomes. Future research could investigate this distinction and weather this analysed factors independent association with hypochloremia. Additionally, hypothesis-driven case-control studies with robust analytical models could further identify patient-level risk factors for hypochloremia, while interventional studies or randomized controlled trials could assess whether active correction influences clinical outcomes. Such investigations would help clarify whether hypochloremia is primarily a marker of disease severity or a modifiable factor in acute heart failure.

Conclusion

In this cohort of adult patients with acute heart failure, the prevalence of hypochloremia at admission was 33.1%, with a mean serum chloride of 99.3 ± 8.4 mmol/L. In-hospital mortality was significantly higher among hypochloremic patients compared to normochloremic patients,and the median length of hospital stay was longer in hypochloremic patients (12 vs 8.5 days, p = 0.001). NYHA class IV, COPD, hyponatremia, and hypokalemia found associated with hypochloremia. Clinically, almost all patients received loop diuretics, often at substantial doses, and a high proportion presented with severe heart failure (NYHA III–IV). These findings suggest that hypochloremia may serve as a marker of disease severity and higher risk of adverse outcomes, highlighting the need for careful electrolyte monitoring and tailored management, particularly in settings with high diuretic exposure and advanced HF.

Limitations

This study limitation includes: its retrospective single-center design, reliance on chart documentation, potential selection bias due to inclusion only of patients with serum chloride measured, lack of standardized diuretic protocols and variable dosing, inability to assess post-discharge or long-term outcomes, and the absence of multivariable outcome modeling for mortality and length of stay.

Supporting information

S1 File. Hypochloremia - SPSS.

(SAV)

pone.0344692.s001.sav (131.3KB, sav)

Data Availability

Data cannot be shared publicly due to the presence of patient-related information, but the data are available from the Jimma University Research Data Repository upon a reasonable request, made by contacting the health institute’s official email at ero@ju.edu.etc.

Funding Statement

This research was funded by Jimma University solely to support the conduct of the study. No specific grants were received for authorship or publication from any public, commercial, or not-for-profit funding agencies. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript Reference: JMU 222/25.

References

  • 1.Stankowski K, Villaschi A, Tartaglia F, Figliozzi S, Pini D, Chiarito M, et al. Prognostic value of hypochloremia on mortality in patients with heart failure: a systematic review and meta-analysis. J Cardiovasc Med (Hagerstown). 2024;25(7):499–510. doi: 10.2459/JCM.0000000000001644 [DOI] [PubMed] [Google Scholar]
  • 2.Solela G. Prevalence and prognostic role of hypochloremia in patients with acute heart failure in Ethiopia: A single-center retrospective analysis. PLoS One. 2024;19(9):e0310251. doi: 10.1371/journal.pone.0310251 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Wu F, Lan Q, Yan L. Prognostic impact of serum chloride concentrations in acute heart failure patients: a systematic review and meta-analysis. Am J Emerg Med. 2023;71:109–16. doi: 10.1016/j.ajem.2023.05.035 [DOI] [PubMed] [Google Scholar]
  • 4.Nozaki Y, Yoshihisa A, Sato Y, Ohara H, Sugawara Y, Abe S, et al. Persistent hypochloremia is associated with adverse prognosis in patients repeatedly hospitalized for heart failure. J Clin Med. 2023;12(4):1257. doi: 10.3390/jcm12041257 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Rivera FB, Alfonso P, Golbin JM, Lo K, Lerma E, Volgman AS, et al. The role of serum chloride in acute and chronic heart failure: a narrative review. Cardiorenal Med. 2021;11(2):87–98. doi: 10.1159/000515604 [DOI] [PubMed] [Google Scholar]
  • 6.Fu Z, An L, Lu X, Sheng L, Liu H. Serum chloride is inversely associated with 3 months outcomes in Chinese patients with heart failure, a retrospective cohort study. Front Cardiovasc Med. 2022;9:855053. doi: 10.3389/fcvm.2022.855053 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.de Peralta García P, Bolzoni M, Yebra Yebra M, Asenjo Martín M, Arrondo Turrado M, Domínguez Sepúlveda MA, et al. Impact of hypochloremia as a prognostic factor in patients with heart failure, a retrospective cohort study. Rev Clin Esp (Barc). 2024;224(5):259–66. doi: 10.1016/j.rceng.2024.04.003 [DOI] [PubMed] [Google Scholar]
  • 8.Arora N. Serum chloride and heart failure. Kidney Med. 2023;5(4):100614. doi: 10.1016/j.xkme.2023.100614 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Ter Maaten JM, Damman K, Hanberg JS, Givertz MM, Metra M, O’Connor CM, et al. Hypochloremia, diuretic resistance, and outcome in patients with acute heart failure. Circ Heart Fail. 2016;9(8):e003109. doi: 10.1161/CIRCHEARTFAILURE.116.003109 [DOI] [PubMed] [Google Scholar]
  • 10.Hanberg JS, Rao V, ter Maaten JM, Laur O, Brisco MA, Perry Wilson F, et al. Hypochloremia and diuretic resistance in heart failure. Circ: Heart Failure. 2016;9(8). doi: 10.1161/circheartfailure.116.003180 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Zandijk AJL. Chloride in heart failure: the neglected electrolyte. J Card Fail. 2021;27:1200–9.doi: 10.1016/j.jchf.2021.07.006 [DOI] [PubMed] [Google Scholar]
  • 12.Chioncel O, Adamo M, Nikolaou M, Parissis J, Mebazaa A, Yilmaz MB, et al. Acute heart failure and valvular heart disease: a scientific statement of the heart failure association, the association for acute cardiovascular care and the European association of percutaneous cardiovascular interventions of the European society of cardiology. Eur J Heart Fail. 2023;25(7):1025–48. doi: 10.1002/ejhf.2918 [DOI] [PubMed] [Google Scholar]
  • 13.Abdi AA, Louis N, Hirsi AM, Nur IA, Mohamud MH, Ali WR, et al. Patterns and factors associated with electrolyte abnormalities among patients with heart failure in Uganda. BMC Cardiovasc Disord. 2024;24(1):618. doi: 10.1186/s12872-024-04276-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Raza S, Ditto SA. Hypochloremia in heart failure: a new prognostic and therapeutic aspect of refractory heart failure. BH. 2024;2(1):2257. doi: 10.36922/bh.2257 [DOI] [Google Scholar]
  • 15.Abraham WT. Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from OPTIMIZE-HF. J Am Coll Cardiol. 2008;52(5):347–56. doi: 10.1016/j.jacc.2008.04.028 [DOI] [PubMed] [Google Scholar]
  • 16.Abraham WT. Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the OPTIMIZE-HF program. J Am Coll Cardiol. 2008;52(5):347–56. doi: 10.1016/j.jacc.2008.04.028 [DOI] [PubMed] [Google Scholar]
  • 17.Gupta H, Sahani KK, Singh MM, Seth G, Gupta A. Impact of dyselectrolytemia on heart failure and their long-term cardiovascular outcomes: a comparative analysis. Adv Clin Med Res. 2021;5(3):1–10. [Google Scholar]
  • 18.Cuthbert JJ, Pellicori P, Rigby A, Pan D, Kazmi S, Shah P, et al. Low serum chloride in patients with chronic heart failure: clinical associations and prognostic significance. Eur J Heart Fail. 2018;20(10):1426–35. doi: 10.1002/ejhf.1247 [DOI] [PubMed] [Google Scholar]
  • 19.Virani SS. Defines AHF spectrum including decompensated states; congestion evidence (clinical/radiological pulmonary, peripheral edema); relevant for acute settings and outcomes like hospital stay/mortality. Circulation. 2021;143:e254–743. doi: 10.1161/CIR.0000000000000950 [DOI] [Google Scholar]
  • 20.Yusuf S. Cardiovascular risk and events in 17 low-, middle-, and high-income countries. N Engl J Med. 2014;371(9):818–27. doi: 10.1056/NEJMoa1311890 [DOI] [PubMed] [Google Scholar]
  • 21.Kondo T, Yamada T, Tamaki S, Morita T, Furukawa Y, Iwasaki Y, et al. Serial change in serum chloride during hospitalization could predict heart failure death in acute decompensated heart failure patients. Circ J. 2018;82(4):1041–50. doi: 10.1253/circj.CJ-17-0938 [DOI] [PubMed] [Google Scholar]
  • 22.Testani JM, Hanberg JS, Arroyo JP, Brisco MA, Ter Maaten JM, Wilson FP, et al. Hypochloraemia is strongly and independently associated with mortality in patients with chronic heart failure. Eur J Heart Fail. 2016;18(6):660–8. doi: 10.1002/ejhf.477 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Chen X, Yin R, Lu M, Mao L, Lu J, Wang M, et al. Prevalence of hypochloremia in patients with heart failure: a systematic review and meta-analysis. Nurs Open. 2025;12(3):e70178. doi: 10.1002/nop2.70178 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.de Peralta García P. Impact of hypochloremia as a prognostic factor in patients with heart failure, a retrospective cohort study. Revista Clínica Española (English Edition). 2024;224(5):259–66. doi: 10.1016/J.RCENG.2024.04.003 [DOI] [PubMed] [Google Scholar]
  • 25.Costache II, Cimpoeşu D, Petriş O, Petriş AO. Electrolyte disturbances in patients with chronic heart failure--clinical, evolutive and therapeutic implications. Rev Med Chir Soc Med Nat Iasi. 2012;116(3):708–13. [PubMed] [Google Scholar]
  • 26.Grodin JL, Testani JM, Pandey A, Sambandam K, Drazner MH, Fang JC, et al. Perturbations in serum chloride homeostasis in heart failure with preserved ejection fraction: insights from TOPCAT. Eur J Heart Fail. 2018;20(10):1436–43. doi: 10.1002/ejhf.1229 [DOI] [PubMed] [Google Scholar]
  • 27.Urso C, Brucculeri S, Caimi G. Acid-base and electrolyte abnormalities in heart failure: pathophysiology and implications. Heart Fail Rev. 2015;20(4):493–503. doi: 10.1007/s10741-015-9482-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Zhang J, Yu Z, Zhu B, Ma J. The association between the hypochloremia and mortality in intensive care unit (ICU) patients with chronic heart failure. J Vascul Dis. 2023;2(2):188–96. doi: 10.3390/jvd2020013 [DOI] [Google Scholar]
  • 29.Li Z, Xing C, Li T, Du L, Wang N. Hypochloremia is associated with increased risk of all-cause mortality in patients in the coronary care unit: a cohort study. J Int Med Res. 2020;48(4):300060520911500. doi: 10.1177/0300060520911500 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Tan Z, Liu Y, Hong K. The association between serum chloride and mortality in ICU patients with heart failure: The impact of bicarbonate. Int J Cardiol. 2024;399:131672. doi: 10.1016/j.ijcard.2023.131672 [DOI] [PubMed] [Google Scholar]
  • 31.Meshesha MD, Kabthymer RH, Abafogi MM. Mortality and its associated factors among hospitalized heart failure patients : the case of South West Ethiopia. Cardiol Res Pract. 2021;2021:5951040. doi: 10.1155/2021/5951040 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Huang H, Mai Z, Chen L, Li Q, Chen S, Bao K, et al. Prevalence and mortality of hypochloremia among patients with coronary artery disease: a cohort study. Risk Manag Healthc Policy. 2021;14:3137–45. doi: 10.2147/RMHP.S306125 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Gupta N, Agrawal S, Chakrabarti S, Ish P. COPD 2020 guidelines - what is new and why?. Adv Respir Med. 2020;88(1):38–40. doi: 10.5603/ARM.2020.0080 [DOI] [PubMed] [Google Scholar]
  • 34.Verbalis JG, Goldsmith SR, Greenberg A, Korzelius C, Schrier RW, Sterns RH, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med. 2013;126(10 Suppl 1):S1-42. doi: 10.1016/j.amjmed.2013.07.006 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Innocent Chukwuonye

11 Jan 2026

Dear Dr.  Kebede,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

The title of the manuscript is quite pertinent and merits attention. Although it is well-written, there are certain issues that should be addressed. The majority of these have been noted by the reviewers. However a few additional issues also need to be addressed.

  1. Sometimes up to five references were cited to support an assertion. Ideally, one to three references is enough.  Five references suggest that you're unsure. I would advise not citing more than three references all at once.

  2. Over half of the studies' cited were written more than five years ago. At least 70% of the mentioned papers should ideally be under five years old. More current articles should be cited. Furthermore, some of the references do not follow the journal reference method.

  3. The ethical approval and consent to participate should be part of the Methods. There is also a need to delete the abbreviations and data availability from the manuscript.

Please submit your revised manuscript by Feb 25 2026 11:59PM.. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

  • A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Innocent Ijezie Chukwuonye, MBBS, FMCP(Internal Medicine)

Academic Editor

PLOS One

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1.Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match.

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

3. Thank you for stating the following financial disclosure:

“This research was funded by Jimma University solely to support the conduct of the study. No specific grants were received for authorship or publication from any public, commercial, or not-for-profit funding agencies.,”

Please state what role the funders took in the study.  If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

If this statement is not correct you must amend it as needed.

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

4. Please note that funding information should not appear in any section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. Please remove any funding-related text from the manuscript.

5. We are unable to open your Supporting Information file “Hypochloremia - SPSS.sav”. Please kindly revise as necessary and re-upload.

6. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript.

7. Please upload a copy of Figure 3, to which you refer in your text on page 22. If the figure is no longer to be included as part of the submission please remove all reference to it within the text.

8. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information .

9. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

Reviewer #1: Partly

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously? -->?>

Reviewer #1: No

Reviewer #2: I Don't Know

**********

3. Have the authors made all data underlying the findings in their manuscript fully available??>

The PLOS Data policy

Reviewer #1: Yes

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #1: Yes

Reviewer #2: No

**********

Reviewer #1: The study addresses an important and underexplored question in acute heart failure (AHF) within a low‑resource African setting and provides clinically relevant data on the prevalence, correlates, and short‑term impact of hypochloremia. The main findings are plausible and broadly consistent with existing literature, but there are significant issues in design description, statistical analysis, clarity, and language that require major revision before the work is suitable for publication.

1. Major issues

1.1 Study design and internal consistency

The manuscript describes the design as an “institution-based cross-sectional study,” yet the analyses clearly involve time‑dependent in‑hospital outcomes (mortality and length of stay). In essence, the study is a retrospective observational cohort (retrospective chart review) of AHF admissions with follow‑up until discharge or death. This inconsistency can confuse readers and undercuts the methodological rigor.

Please re‑classify and consistently describe the design as a retrospective observational or retrospective cohort study of hospitalized AHF patients with serum chloride measured at admission.

Clarify the study flow: total number of AHF admissions during the period, number excluded for missing chloride or incomplete records, and final number analyzed. A simple flow diagram would be helpful.

1.2 Operational definitions and exposure–outcome structure

The manuscript provides detailed operational definitions (AHF, hypochloremia, hyponatremia, HF phenotypes, etc.), which is commendable. However, the roles of some defined constructs are not clearly integrated into the analysis:

“Corrected” vs “persistent” hypochloremia are defined but not meaningfully analyzed beyond basic counts.

The primary exposure appears to be hypochloremia at admission, but this is not explicitly declared as such in the Methods.

Please:

Explicitly state the primary exposure (hypochloremia at admission) and primary outcomes (in‑hospital mortality and length of hospital stay).

Either remove “corrected/persistent hypochloremia” from the operational definitions or include a clearly planned secondary analysis comparing their prognostic impact, if the data allow.

1.3 Statistical analysis and claims of prognostic independence

The descriptive analyses, Chi‑square test for mortality, and Mann–Whitney U test for length of stay are appropriate for unadjusted comparisons. The multivariable logistic regression for predictors of hypochloremia is also appropriate in principle, and the reported associations with NYHA class IV, COPD, hyponatremia, and hypokalemia are clinically plausible. However:

There is no multivariable model assessing whether hypochloremia independently predicts in‑hospital mortality or length of stay after adjustment for other markers of disease severity (age, NYHA class, ejection fraction, renal function, sodium, potassium, diuretic dose, comorbidities).

Despite this, parts of the Discussion and Conclusion imply that hypochloremia is an independent prognostic factor in this cohort.

To strengthen the manuscript and support prognostic claims, the following are strongly recommended:

Construct a multivariable logistic regression model for in‑hospital mortality including at minimum: age, sex, NYHA class, HF phenotype (HFrEF/HFpEF/HFmrEF), COPD, renal function (creatinine or eGFR), sodium, potassium, loop diuretic use/dose, and hypochloremia at admission.

Consider a multivariable model for length of stay (e.g., negative binomial/Poisson or linear regression on log‑transformed LOS) with the same covariates, including hypochloremia.

Clearly describe variable selection (clinical vs p‑value–based), check for multicollinearity, and report model fit indices (in addition to the Hosmer‑Lemeshow test).

If you are unable to perform adjusted outcome models, the wording throughout the manuscript should be revised to emphasize associations rather than independent prognostic effects, and this limitation should be explicitly acknowledged.

1.4 Sampling, sample size, and potential selection bias

The sample size calculation is described but not completely transparent. The text mentions an assumed prevalence of 36.7% and initial sample size of 357, then a finite population correction based on 700 AHF patients to reach 260, but the intermediate steps are not shown. Moreover, “systematic random sampling” is stated without sufficient detail.

Please show the exact formula and parameters used (P, Z, d, N) and the calculation steps leading to 357 and then 260.

Justify the estimate of 700 AHF patients (e.g., internal hospital statistics for the defined period).

Describe the systematic sampling method more clearly: how were records ordered, what was the sampling interval (k), how was the random starting point chosen, and how were ineligible or missing charts handled.

Discuss the potential for selection bias due to inclusion only of patients with serum chloride measured at admission and how this might affect generalizability.

2. Presentation of results

2.1 Descriptive characteristics and tables

The manuscript provides a good overview of baseline clinical, laboratory, and treatment characteristics. There are, however, several areas that require clarification or correction:

Typographical and wording errors (e.g., “A of total 260…”, “peripheral enema” instead of “peripheral edema”, “de nevo” instead of “de novo”) should be corrected throughout.

Table 1 and subsequent tables need to strictly follow journal style: include clear titles, units, denominators, and footnotes explaining any abbreviations.

For interpretability, a dedicated table comparing key baseline characteristics between hypochloremic and non‑hypochloremic groups (demographics, comorbidities, HF type, NYHA class, renal function, sodium, potassium, diuretic use and dose) would be very useful.

2.2 Main findings

The key results are clearly presented:

Prevalence of hypochloremia 33.1% (86/260), mean chloride 99.3 ± 8.4 mmol/L (range 70–136).

In‑hospital mortality significantly higher in hypochloremic patients (15.1%) compared to normochloremic patients (4.5%), p = 0.003.

Median length of stay longer in hypochloremic patients (12 days vs 8.5 days), p = 0.001.

In multivariable analysis, NYHA class IV, COPD, hyponatremia, and hypokalemia remain significantly associated with hypochloremia.

These findings are important and potentially practice‑influencing for settings similar to the study site, especially given the high loop diuretic exposure documented. The manuscript would benefit from explicitly highlighting the clinical context, such as treatment patterns (almost all on loop diuretics, substantial doses) and the severity of HF at presentation (high proportion of NYHA III–IV).

3. Discussion and interpretation

The Discussion appropriately situates the results in the context of prior work from Ethiopia, Asia, Europe, and North America and offers plausible pathophysiologic explanations (RAAS activation, diuretic resistance, neurohormonal activation, volume overload). Nonetheless, several aspects need refinement:

At times, the narrative appears to imply a causal relationship between hypochloremia and poor outcomes, whereas the current analysis is largely observational and unadjusted for key confounders.

Statements that hypochloremia is a “strong prognostic indicator” should be tempered or supported by adjusted outcome models as suggested above.

The concept of “non-medication related associated factors” in the title and abstract is not clearly developed in the Discussion; medications (loop diuretics, RAAS blockers, SGLT2 inhibitors) are described but not systematically analyzed as predictors of hypochloremia.

Recommended revisions:

Reframe conclusions to emphasize that hypochloremia is associated with worse in‑hospital outcomes and more severe clinical profiles, but that residual confounding cannot be excluded.

If medication effects are of special interest, include them explicitly in the multivariable model for hypochloremia and discuss their role relative to “non‑medication” factors; otherwise, consider removing “Non‑Medication Related” from the title.

Add a more explicit hypothesis‑generating statement that future prospective and interventional studies are needed to determine whether active correction of hypochloremia improves outcomes.

4. Limitations and generalizability

The limitations section is relatively brief and should be expanded. At minimum, please address:

Retrospective single‑center design and reliance on chart documentation, which may introduce misclassification of AHF diagnosis, comorbidities, and outcomes.

Potential selection bias due to inclusion only of patients with serum chloride measured, which may oversample more severe or more closely monitored cases.

Lack of standardized diuretic protocols and possible confounding by varying diuretic dose and duration.

Inability to assess post‑discharge or long‑term outcomes; the prognostic assessment is limited to in‑hospital events.

Absence (in current form) of multivariable outcome modeling to fully establish independent association between hypochloremia and mortality/length of stay.

These additions will improve transparency and help readers interpret the findings in the appropriate context.

5. Ethics, data availability, and reporting

Ethics approval and confidentiality measures are reported, which is essential. However, the ethics paragraph appears to contain an incomplete phrase (“in accordance with the Declaration of…”) and should be corrected to “Declaration of Helsinki” or similar, as applicable.

The Data Availability statement in the manuscript and the Editorial Manager fields both state that all relevant data are within the manuscript and supporting files, but the wording appears somewhat duplicated and fragmented. For a PLOS ONE submission, please:

Ensure a single, clear Data Availability statement is included in the manuscript, fully aligned with journal policy and exactly matching what is declared in the submission system.

If possible, consider depositing a de‑identified dataset in a suitable public repository and provide the link/DOI, which would increase transparency and reuse potential.

6. Language, style, and formatting

The manuscript contains numerous grammatical errors, awkward phrases, and typographical issues that impede readability. Examples include incorrect word choices, spacing, and inconsistencies in terms and abbreviations.

A thorough language and copy‑editing pass, preferably by a fluent English speaker or professional editor, is strongly recommended before resubmission.

Ensure consistent use of terminology and abbreviations (e.g., NYHA, HFpEF, HFrEF, HFmrEF, COPD, etc.), and define each abbreviation at first use.

Standardize reference formatting according to PLOS ONE guidelines; verify journal names, year, volume/issue, pages, and DOIs where applicable.

7. Overall evaluation

In summary, this manuscript addresses a relevant and insufficiently studied topic—the prevalence and short‑term impact of hypochloremia in AHF patients in a resource‑limited African setting—and contributes potentially important data. However, several methodological and reporting issues (design labeling, incomplete description of sampling and analysis, absence of adjusted models for outcomes, and language/formatting problems) need substantial revision. With careful attention to the points above, the study could provide a valuable addition to the literature on electrolyte disturbances and heart failure, particularly in low‑resource contexts.

Reviewer #2: Reviewer’s feedback based on research articles using the following criteria:

1. The study presents the results of original research.

a. The study met this criterion by collecting original data locally at the Jimma Medical Center (JMC) by including only patients on admission using serum chlorine level.

2. Results reported have not been published elsewhere.

a. Not sure it has been published elsewhere.

3. Experiments, statistics, and other analyses are performed to a high technical standard and are described in sufficient detail.

a. The manuscript reports a hospital-based cross-sectional study using retrospective medical records. The authors clearly describe the sampling approach, and the sample size appears adequate for the stated analyses. Data were extracted retrospectively using a structured checklist by trained residents (via Kobo Toolbox) under PI supervision. Quality assurance procedures are also described, including a 5% pretest at a separate hospital to improve clarity, routine/daily review, cross-checking, and PI oversight. However, the Methods do not explain how missing data were assessed or handled (e.g., extent of missingness, exclusions, or imputation), which limits reproducibility and may affect interpretation of the results.

4. Conclusions are presented in an appropriate fashion and are supported by the data.

a. For (i) and (ii), since this study is a cross-sectional study, authors should not overstate that correcting hypochloremia improves health outcome since authors did not directly test for in the study. My suggestion: they should be revised to show association only; authors should consider framing any hypotheses for future studies.

i. “Early recognition and correction of hypochloremia may improve outcomes in this population.”

ii. “These findings highlight the importance of early identification and correction 333 of electrolyte imbalances, particularly hypochloremia, to potentially improve outcomes in 334 patients with acute heart failure.

b. In the Discussion, the authors imply that hypochloremia affects healthcare costs and system burden; however, cost/resource utilization outcomes were not measured in this study. Please revise this statement to reflect with the data in the study (i.e., the observed difference in length of stay) and frame any cost/burden implications as speculative or remove them.

5. The article is presented in an intelligible fashion and is written in standard English.

Article is understandable and readable, but I think authors need to pay more attention to the ethical statement part and result section as they might appear to be some grammatically error, and punctuation issue. “Participants names were not be recorded…” and “The study was conducted in accordance with the Declaration of…” that part seem incomplete.

6. The research meets all applicable standards for the ethics of experimentation and research integrity.

Manuscript met all ethical declaration the ethics statement should be revised for clarity (one sentence is incomplete), and the authors should consider adding the IRB approval reference/number and approval date to improve transparency.

7. The article adheres to appropriate reporting guidelines and community standards for data availability.

Authors should clarify what can be shared (de-identified dataset, codebook, analysis code) and the process/approvals required considering their data is clinical.

**********

what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy

Reviewer #1: Yes: Deepanshu

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures

You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation.

NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications.

PLoS One. 2026 Mar 19;21(3):e0344692. doi: 10.1371/journal.pone.0344692.r002

Author response to Decision Letter 1


24 Jan 2026

Editor comment

1- Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Answer

We thank the Editor and reviewers for their careful evaluation of our manuscript and for recognizing its merit. We have revised the manuscript thoroughly to address all points raised during the review process. We believe that these revisions have substantially improved the clarity, rigor, and overall quality of the manuscript, and we hope that the revised version now meets the publication criteria of PLOS ONE.

2- The title of the manuscript is quite pertinent and merits attention. Although it is well-written, there are certain issues that should be addressed. The majority of these have been noted by the reviewers. However a few additional issues also need to be addressed.

Answer:

We thank the Editor for the positive assessment of the manuscript title and overall writing quality. We have carefully addressed all issues raised by the reviewers, as well as the additional concerns noted by the Editor. Appropriate revisions have been made throughout the manuscript to improve clarity, consistency, and scientific rigor. We believe these changes have strengthened the manuscript substantially.

3- Sometimes up to five references were cited to support an assertion. Ideally, one to three references are enough. Five references suggest that you're unsure. I would advise not citing more than three references all at once.

Answer: We thank the reviewer for this helpful suggestion. We have revised the manuscript to limit the number of references supporting a single assertion to a maximum of three, citing only the most relevant and authoritative sources.

4- Over half of the studies cited were written more than five years ago. At least 70% of the mentioned papers should ideally be under five years old. More current articles should be cited. Furthermore, some of the references do not follow the journal reference method.

Answer;

Thank you for your comment. We have revised the references in the manuscript to ensure that the majority are from the last five years, with at least 70% of cited studies being recent and directly relevant. We have also carefully reformatted all references to fully comply with the PLOS ONE referencing style, including journal names, volume, issue, pages, and DOI numbers where available.

5- The ethical approval and consent to participate should be part of the Methods. There is also a need to delete the abbreviations and data availability from the manuscript.

Answer

We thank the Editor for this important comment. The information on ethical approval and consent to participate has now been moved to the Methods section. In addition, the Abbreviations and Data Availability sections have been removed from the manuscript in accordance with the journal’s requirements.

6- A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

Answer

We thank the Editor for this instruction. A detailed point-by-point response addressing all comments raised by the Academic Editor and the reviewers has been prepared and uploaded as a separate file entitled “Response to Reviewers.”

7- A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

Answer: We thank the Editor for this instruction. A marked-up version of the manuscript highlighting all revisions has been prepared and uploaded as a separate file entitled “Revised Manuscript with Track Changes.”

8- An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

Anwer

We thank the Editor for this instruction. An unmarked version of the revised manuscript, without tracked changes, has been prepared and uploaded as a separate file entitled “Manuscript.”

9- If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

10- If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

Answer:

We appreciate the suggestion. While our study did not involve novel laboratory protocols, all procedures followed standard clinical and laboratory practices. We have ensured that methods are described in sufficient detail to allow reproducibility. Since no unique protocols were developed, deposition in protocols.io was not applicable.

11- Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

Answer

We have ensured that the manuscript fully complies with PLOS ONE style requirements, including formatting and file naming conventions. The manuscript has been prepared using the official PLOS ONE style templates, which are available on the PLOS ONE website.

12- We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

Answer:

We appreciate your observation. We have reviewed the sections and corrected the discrepancies. The Funding Information and Financial Disclosure sections now consistently reflect the same grant source, number, and supporting institution.

13- .Thank you for stating the following financial disclosure: “This research was funded by Jimma University solely to support the conduct of the study. No specific grants were received for authorship or publication from any public, commercial, or not-for-profit funding agencies.,”

Answer

Funding

This research was funded by Jimma University solely to support the conduct of the study. No specific grants were received for authorship or publication from any public, commercial, or not-for-profit funding agencies. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript Reference: JMU 222/25

Accept and corrected

14- Please state what role the funders took in the study. If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." If this statement is not correct you must amend it as needed.

Answer

Accept and corrected as provides

15- Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

Answer

Accept and corrected as provides

16- Please note that funding information should not appear in any section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. Please remove any funding-related text from the manuscript.

Answer

Accept and corrected as provides

15. We are unable to open your Supporting Information file “Hypochloremia - SPSS.sav”. Please kindly revise as necessary and re-upload.

Answer

Accept and corrected as provides

16. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript.

Answer

Accept and corrected as provides

17. Please upload a copy of Figure 3, to which you refer in your text on page 22. If the figure is no longer to be included as part of the submission please remove all reference to it within the text.

Answer

Accept and corrected as provides

18. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

Answer: We have added captions for all Supporting Information files at the end of the manuscript and updated the corresponding in-text citations to match, in accordance with PLOS ONE’s Supporting Information guidelines.

19. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

Answer

We thank the reviewer for the suggested references. We carefully reviewed the recommended publications and cited those that are directly relevant and contribute to the context and interpretation of our findings. References that were not cited were determined to be outside the scope of the present study.

Review Comments to the Author

Reviewer #1: The study addresses an important and underexplored question in acute heart failure (AHF) within a low‑resource African setting and provides clinically relevant data on the prevalence, correlates, and short‑term impact of hypochloremia. The main findings are plausible and broadly consistent with existing literature, but there are significant issues in design description, statistical analysis, clarity, and language that require major revision before the work is suitable for publication.

Answer;

We thank the reviewer for acknowledging the clinical relevance of our study. We have addressed the concerns by revising the study design description, clarifying the statistical analysis, and improving language and overall manuscript clarity. These changes enhance the rigor and readability of the work.

1. Major issues

1.1 Study design and internal consistency

The manuscript describes the design as an “institution-based cross-sectional study,” yet the analyses clearly involve time‑dependent in‑hospital outcomes (mortality and length of stay). In essence, the study is a retrospective observational cohort (retrospective chart review) of AHF admissions with follow‑up until discharge or death. This inconsistency can confuse readers and undercut the methodological rigor.

Answer

Thank you for the comment. We have clarified the study design and now consistently describe the study as a retrospective observational cohort study throughout the manuscript, including the Methods section.

Please re‑classify and consistently describe the design as a retrospective observational or retrospective cohort study of hospitalized AHF patients with serum chloride measured at admission.

Answer

Thank you for this comment. We have reclassified and consistently described the study design as a retrospective observational cohort study of hospitalized patients with acute heart failure, with serum chloride measured at admission, throughout the manuscript (including the Abstract and Methods sections).

Clarify the study flow: total number of AHF admissions during the period, number excluded for missing chloride or incomplete records, and final number analyzed. A simple flow diagram would be helpful.

Answer:

Thank you for this helpful suggestion. We have clarified the study flow by reporting the total number of acute heart failure (AHF) admissions during the study period, the number of patients excluded due to missing serum chloride measurements or incomplete records, and the final number included in the analysis. In addition, we have added a simple flow diagram to visually illustrate the patient selection process.

1.2 Operational definitions and exposure–outcome structure

The manuscript provides detailed operational definitions (AHF, hypochloremia, hyponatremia, HF phenotypes, etc.), which is commendable. However, the roles of some defined constructs are not clearly integrated into the analysis:

“Corrected” vs “persistent” hypochloremia are defined but not meaningfully analyzed beyond basic counts.

Answer

Thank you for this comment. We agree with the reviewer that corrected and persistent hypochloremia were not meaningfully analyzed in the present study. As the analysis was limited to hypochloremia at admission, as we also revised the Methods section accordingly and removed the definitions of corrected and persistent hypochloremia from the operational definitions to ensure consistency between the study objectives, methods, and analyses.

The primary exposure appears to be hypochloremia at admission, but this is not explicitly declared as such in the Methods.

Answer

Thank you for this comment. We have revised the Methods section to explicitly state that the primary exposure in this study is hypochloremia at admission. This clarification ensures that the study objectives, exposure definition, and analysis are clearly aligned.

Explicitly state the primary exposure (hypochloremia at admission) and primary outcomes (in‑hospital mortality and length of hospital stay).

Answer.

Thank you for this comment. We have revised the Methods section to explicitly state that the primary exposure is hypochloremia at admission, and the primary outcomes are in-hospital mortality and length of hospital stay. This clarification ensures alignment between the study objectives, exposure, and outcome measures.

Either remove “corrected/persistent hypochloremia” from the operational definitions or include a clearly planned secondary analysis comparing their prognostic impact, if the data allow.

Answer

Thank you for this suggestion. As the present study focuses on hypochloremia at admission and we did not perform a secondary analysis of corrected or persistent hypochloremia, we have removed these terms from the operational definitions to maintain consistency between the study objectives, methods, and analysis.

1.3 Statistical analysis and claims of prognostic independence

The descriptive analyses, Chi‑square test for mortality, and Mann–Whitney U test for length of stay are appropriate for unadjusted comparisons. The multivariable logistic regression for predictors of hypochloremia is also appropriate in principle, and the reported associations with NYHA class IV, COPD, hyponatremia, and hypokalemia are clinically plausible. However: There is no multivariable model assessing whether hypochloremia independently predicts in‑hospital mortality or length of stay after adjustment for other markers of disease severity (age, NYHA class, ejection fraction, renal function, sodium, potassium, diuretic dose, comorbidities). Despite this, parts of the Discussion and Conclusion imply that hypochloremia is an independent prognostic factor in this cohort. To strengthen the manuscript and support prognostic claims, the following are strongly recommended: Construct a multivariable logistic regression model for in‑hospital mortality including at minimum: age, sex, NYHA class, HF phenotype (HFrEF/HFpEF/HFmrEF), COPD, renal function (creatinine or eGFR), sodium, potassium, loop diuretic use/dose, and hypochloremia at admission. Consider a multivariable model for length of stay (e.g., negative binomial/Poisson or linear regression on log‑transformed LOS) with the same covariates, including hypochloremia. Clearly describe variable selection (clinical vs p‑value–based), check for multi

Attachment

Submitted filename: Response to reviewr.docx

pone.0344692.s002.docx (36KB, docx)

Decision Letter 1

Innocent Chukwuonye

24 Feb 2026

Hypochloremia, Non-Medication Related Associated Factors, and Impact on Clinical Outcomes in Patients with Acute Heart Failure: Insights from Resource limited setups

PONE-D-25-64426R1

Dear Dr. ,Molla Asnake Kebede

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager®  and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support .

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Innocent Ijezie Chukwuonye, MBBS, FMCP (Internal Medicine)

Academic Editor

PLOS One

Acceptance letter

Innocent Chukwuonye

PONE-D-25-64426R1

PLOS One

Dear Dr. Kebede,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Innocent Ijezie Chukwuonye

Academic Editor

PLOS One

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File. Hypochloremia - SPSS.

    (SAV)

    pone.0344692.s001.sav (131.3KB, sav)
    Attachment

    Submitted filename: Response to reviewr.docx

    pone.0344692.s002.docx (36KB, docx)

    Data Availability Statement

    Data cannot be shared publicly due to the presence of patient-related information, but the data are available from the Jimma University Research Data Repository upon a reasonable request, made by contacting the health institute’s official email at ero@ju.edu.etc.


    Articles from PLOS One are provided here courtesy of PLOS

    RESOURCES